APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026

29 December 2025201 pages

Choose your research edition.

Industry ResearchLong-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA and Evive Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company

Amgen

Mylan

Kashiv BioSciences

Pfizer

Fresenius Kabi

Coherus BioSciences

Sandoz

Italfarmaco SpA

Evive Biotech

Chugai Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Amoytop Biotech

Qilu Pharmaceutical

CSPC Baike Biopharma

SL Pharm

Lunan Pharmaceutical

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Lenograstim

Pegfilgrastim

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Hospital and Clinic

Pharmacy

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) industry.

Chapter 3: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends Table 2. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers Table 3. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges Table 4. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints Table 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Company (2021-2026) Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Company (2021-2026) Table 9. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Company Manufacturing Base & Headquarters Table 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company, Product Type & Application Table 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lenograstim Table 18. Significant Companies of Pegfilgrastim Table 19. Significant Companies of Other Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2021-2026) Table 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2027-2032) Table 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2021-2026) Table 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital and Clinic Table 31. Significant Companies of Pharmacy Table 32. Significant Companies of Other Table 33. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2021-2026) Table 37. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2027-2032) Table 38. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2021-2026) Table 42. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2027-2032) Table 43. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (K Units) Table 45. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026) Table 46. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032) & (K Units) Table 47. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2027-2032) Table 48. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Region (2021-2026) Table 51. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Region (2027-2032) Table 53. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 58. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2026) Table 59. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 60. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2027-2032) Table 61. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Market Share by Country (2021-2026) Table 63. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Market Share by Country (2027-2032) Table 65. Amgen Company Information Table 66. Amgen Business Overview Table 67. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 69. Amgen Recent Development Table 70. Mylan Company Information Table 71. Mylan Business Overview Table 72. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 74. Mylan Recent Development Table 75. Kashiv BioSciences Company Information Table 76. Kashiv BioSciences Business Overview Table 77. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 79. Kashiv BioSciences Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 84. Pfizer Recent Development Table 85. Fresenius Kabi Company Information Table 86. Fresenius Kabi Business Overview Table 87. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 89. Fresenius Kabi Recent Development Table 90. Coherus BioSciences Company Information Table 91. Coherus BioSciences Business Overview Table 92. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 94. Coherus BioSciences Recent Development Table 95. Sandoz Company Information Table 96. Sandoz Business Overview Table 97. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 99. Sandoz Recent Development Table 100. Italfarmaco SpA Company Information Table 101. Italfarmaco SpA Business Overview Table 102. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 104. Italfarmaco SpA Recent Development Table 105. Evive Biotech Company Information Table 106. Evive Biotech Business Overview Table 107. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 109. Evive Biotech Recent Development Table 110. Chugai Pharmaceutical Company Information Table 111. Chugai Pharmaceutical Business Overview Table 112. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 114. Chugai Pharmaceutical Recent Development Table 115. Jiangsu Hengrui Pharmaceuticals Company Information Table 116. Jiangsu Hengrui Pharmaceuticals Business Overview Table 117. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 119. Jiangsu Hengrui Pharmaceuticals Recent Development Table 120. Amoytop Biotech Company Information Table 121. Amoytop Biotech Business Overview Table 122. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 124. Amoytop Biotech Recent Development Table 125. Qilu Pharmaceutical Company Information Table 126. Qilu Pharmaceutical Business Overview Table 127. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 129. Qilu Pharmaceutical Recent Development Table 130. CSPC Baike Biopharma Company Information Table 131. CSPC Baike Biopharma Business Overview Table 132. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 134. CSPC Baike Biopharma Recent Development Table 135. SL Pharm Company Information Table 136. SL Pharm Business Overview Table 137. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 139. SL Pharm Recent Development Table 140. Lunan Pharmaceutical Company Information Table 141. Lunan Pharmaceutical Business Overview Table 142. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 144. Lunan Pharmaceutical Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List Table 148. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Image Figure 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032) & (K Units) Figure 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lenograstim Image Figure 10. Pegfilgrastim Image Figure 11. Other Image Figure 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2021-2032) Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2021-2032) Figure 18. Hospital and Clinic Image Figure 19. Pharmacy Image Figure 20. Other Image Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2021-2032) Figure 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2021-2032) Figure 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Lenograstim
  • Pegfilgrastim
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Amgen
  • Mylan
  • Kashiv BioSciences
  • Pfizer
  • Fresenius Kabi
  • Coherus BioSciences
  • Sandoz
  • Italfarmaco SpA
  • Evive Biotech
  • Chugai Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • CSPC Baike Biopharma
  • SL Pharm
  • Lunan Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  4. 1.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume (2021-2032)
  5. 1.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
  1. 2.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
  2. 2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
  3. 2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
  4. 2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Company
  1. 3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Company (2021-2026)
  4. 3.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Company (2021-2026)
  5. 3.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Ranking (2024-2026)
  6. 3.6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Manufacturing Base and Headquarters
  7. 3.7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Product Type and Application
  8. 3.8 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
  1. 4.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Type Introduction
  2. 4.1.1 Lenograstim
  3. 4.1.2 Pegfilgrastim
  4. 4.1.3 Other
  5. 4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type
  6. 4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type
  10. 4.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021-2032)
  12. 4.3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2021-2032)
5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
  1. 5.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application
  6. 5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application
  10. 5.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2021-2032)
6 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Regional Sales and Value Analysis
  1. 6.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021-2026
  4. 6.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032)
  5. 6.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2027-2032)
  9. 6.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  12. 6.6.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  15. 6.7.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  21. 6.9.2 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
7 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Country-level Sales and Value Analysis
  1. 7.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  4. 7.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
  5. 7.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032)
  6. 7.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 Kashiv BioSciences
  14. 8.3.1 Kashiv BioSciences Company Information
  15. 8.3.2 Kashiv BioSciences Business Overview
  16. 8.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  18. 8.3.5 Kashiv BioSciences Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Fresenius Kabi
  26. 8.5.1 Fresenius Kabi Company Information
  27. 8.5.2 Fresenius Kabi Business Overview
  28. 8.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  30. 8.5.5 Fresenius Kabi Recent Developments
  31. 8.6 Coherus BioSciences
  32. 8.6.1 Coherus BioSciences Company Information
  33. 8.6.2 Coherus BioSciences Business Overview
  34. 8.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  36. 8.6.5 Coherus BioSciences Recent Developments
  37. 8.7 Sandoz
  38. 8.7.1 Sandoz Company Information
  39. 8.7.2 Sandoz Business Overview
  40. 8.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  42. 8.7.5 Sandoz Recent Developments
  43. 8.8 Italfarmaco SpA
  44. 8.8.1 Italfarmaco SpA Company Information
  45. 8.8.2 Italfarmaco SpA Business Overview
  46. 8.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  48. 8.8.5 Italfarmaco SpA Recent Developments
  49. 8.9 Evive Biotech
  50. 8.9.1 Evive Biotech Company Information
  51. 8.9.2 Evive Biotech Business Overview
  52. 8.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  54. 8.9.5 Evive Biotech Recent Developments
  55. 8.10 Chugai Pharmaceutical
  56. 8.10.1 Chugai Pharmaceutical Company Information
  57. 8.10.2 Chugai Pharmaceutical Business Overview
  58. 8.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  60. 8.10.5 Chugai Pharmaceutical Recent Developments
  61. 8.11 Jiangsu Hengrui Pharmaceuticals
  62. 8.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 8.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 8.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  66. 8.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 8.12 Amoytop Biotech
  68. 8.12.1 Amoytop Biotech Company Information
  69. 8.12.2 Amoytop Biotech Business Overview
  70. 8.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  72. 8.12.5 Amoytop Biotech Recent Developments
  73. 8.13 Qilu Pharmaceutical
  74. 8.13.1 Qilu Pharmaceutical Company Information
  75. 8.13.2 Qilu Pharmaceutical Business Overview
  76. 8.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  78. 8.13.5 Qilu Pharmaceutical Recent Developments
  79. 8.14 CSPC Baike Biopharma
  80. 8.14.1 CSPC Baike Biopharma Company Information
  81. 8.14.2 CSPC Baike Biopharma Business Overview
  82. 8.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  84. 8.14.5 CSPC Baike Biopharma Recent Developments
  85. 8.15 SL Pharm
  86. 8.15.1 SL Pharm Company Information
  87. 8.15.2 SL Pharm Business Overview
  88. 8.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  90. 8.15.5 SL Pharm Recent Developments
  91. 8.16 Lunan Pharmaceutical
  92. 8.16.1 Lunan Pharmaceutical Company Information
  93. 8.16.2 Lunan Pharmaceutical Business Overview
  94. 8.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  96. 8.16.5 Lunan Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
  2. 9.1.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Mode & Process
  6. 9.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
  9. 9.2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst